199 long-form reviews of the compounds, tests and recovery tools people actually buy — each one built on 1377 peer-reviewed citations in total, and each one honest about where the trials failed.
Every article links to its primary sources, names the trials that missed their endpoints, and states plainly where the human evidence stops. Evidence grades are set independently of affiliate commissions. Browse by topic below, or jump to the evidence-graded supplement guide, the longevity pathway map, or the full research map.
84 articles · topic hub → · shop this category →
What the evidence actually shows about resveratrol's healthspan potential, from bone density to knee pain.
The evidence for acetyl-L-carnitine is limited to specific conditions, with no direct support for lifespan extension.
Where the evidence lands: Acetyl-L-carnitine (ALCAR) shows some evidence for specific benefits in diabetic neuropathy, prefrailty, and dementia, but it is not supported as a general longevity or healthspan enhancer.
What the evidence actually shows about this popular supplement.
Where the evidence lands: Ubiquinol shows specific benefits for endothelial function in heart failure and migraine prevention, but evidence for broad longevity claims is lacking.
A July 2026 Nature Reviews Genetics review from the lab that discovered fisetin's senolytic activity says the field still cannot reliably tell a senescent cell from another cell fate. The…
Where the evidence lands: Senolytics rest on strong mouse data and a short list of small human trials that almost all used prescription dasatinib alongside quercetin. The largest randomised test in ordinary ageing people missed its primary endpoint, benefit appeared only in an exploratory subgroup defined by a research-only assay, and fisetin's human evidence is mostly absorption studies. There is still no validated way to measure your own senescent cell burden.
Ranked by the strength of human evidence for an outcome that matters, not by mechanism. Creatine, protein, HMB and a daily multivitamin have randomized trials with functional endpoints.…
Where the evidence lands: Nothing in this evidence base tested human lifespan; every result below is a proxy. The best-supported compounds are cheap and pair with resistance training: creatine added 1.37 kg of lean tissue across 22 RCTs and 721 older adults; HMB added 4.61 kg of grip strength and 0.11 m/s of gait speed over 12 weeks in 34 sarcopenic adults; whey improved gait speed and muscle mass in 1,154 sarcopenic patients, though a stricter synthesis found the grip gain (+2.31 kg) below the minimally important difference. A daily multivitamin improved memory in COSMOS-Web (3,562 adults) by the equivalent of 3.1 years of age-related memory change, but in COSMOS-Mind it did not lower incident MCI or dementia. Large trials were null for hard endpoints: VITAL found HRs of 0.96 (cancer) and 0.97 (CVD) for vitamin D and 0.92 (CVD) for omega-3; DO-HEALTH found nothing across six primary endpoints in 2,157 adults. Urolithin A, NMN, spermidine, fisetin and taurine have biomarker data, exploratory signals, or null primary endpoints only. Beta-carotene raised all-cause mortality (RR 1.10) in the 884-trial micronutrient synthesis.
Oral NMN and nicotinamide riboside reliably raise blood NAD+ — nicotinamide riboside by 22% to 142% depending on dose. Across randomized trials, grip strength, gait speed, insulin…
Where the evidence lands: NAD precursors do the biochemical thing they claim. Nicotinamide riboside raised whole blood NAD+ by 22%, 51% and 142% at 100, 300 and 1000 mg/day over eight weeks; NMN raised blood NAD significantly at 300, 600 and 900 mg/day over 60 days in 80 adults; pharmaceutical NMN moved NAD+ from 16.0 to 42.6 µg/mL in 14 days. Clinical outcomes are another matter. A 2025 meta-analysis found no NMN effect on skeletal muscle index (MD −0.42, p=0.14), gait speed (MD −0.01, p=0.79) or chair-stand time. NR did not improve clamp-measured insulin sensitivity in 40 obese men, or cognition in two MCI trials that doubled or 2.6-folded blood NAD+. Raising NAD+ nearly threefold in 42 hospitalised COVID-19 patients left creatinine, CRP, IL-6 and TNFα unchanged. Positives exist — sleep quality and four-metre walk time as secondary endpoints in a trial whose primary was null, LDL and diastolic blood pressure in a 30-person 28-day study. Doses studied: 250 mg–2 g/day NMN, 1000–3000 mg/day NR. No trial has compared NMN with NR head-to-head, and no outcomes trial of IV NAD+ for anti-aging or wellness indications exists.
It is manufactured by an organ, carried on a binding protein, activated in two hydroxylation steps and read by a nuclear receptor — and the trials behave exactly as that biology predicts.
Where the evidence lands: Vitamin D is a secosteroid hormone that was named as a vitamin in the era when it was found in cod liver oil. Because it runs on a feedback loop rather than a supply curve, repletion is where the benefit lives: the two largest trials were null on their primary endpoints in already-replete populations, and an annual 500,000 IU bolus increased falls and fractures instead of reducing them.
A landmark three-year trial preserved knee joint space while the larger NIH GAIT trial found glucosamine no better than placebo — and the much-shared mortality association is…
Where the evidence lands: For knee osteoarthritis the trial record is genuinely split and guidelines disagree; the lifespan signal (hazard ratio 0.85) is association, not causation.
The giant COSMOS trial gave cocoa flavanols the fairest test any supplement has had. The headline outcome was null; the secondary results were intriguing; the honest reading is 'component…
Where the evidence lands: In the COSMOS randomized trial, daily cocoa extract did not significantly reduce total cardiovascular events, though cardiovascular death was 27% lower in secondary analyses; smaller trials show modest vascular benefits (+1.2 points of flow-mediated dilation, ~2 mmHg blood pressure), and cognition and diabetes-prevention outcomes were null.
Green tea catechins produce small but measurable metabolic effects in pooled randomized trials, and habitual tea drinking tracks with lower mortality in huge cohorts. Concentrated…
Where the evidence lands: Expect modesty: pooled trials show green tea catechins yield on the order of 1 kg of weight loss and small improvements in cholesterol, blood pressure and glucose — often judged not clinically meaningful — while observational links to 9–13% lower mortality cannot prove cause, and EGCG intakes at or above about 800 mg/day carry a flagged liver-injury risk.
Marine omega-3s reliably lower triglycerides and modestly lower blood pressure — and yet the giant cardiovascular trials disagree with each other in instructive ways, including one where…
Where the evidence lands: EPA/DHA supplements reliably reduce triglycerides (roughly 15% at higher doses), and high-dose purified EPA cut ischemic events by 25% in statin-treated patients with elevated triglycerides — but 1 g/day blends did little in primary prevention, Cochrane found little or no mortality benefit, and doses above 1 g/day raise atrial fibrillation risk.
Beta-alanine reliably raises muscle carnosine and produces a small but statistically real ergogenic effect for high-intensity efforts of roughly one to four minutes; benefits for strength,…
Where the evidence lands: A safe, modest tool for the one-to-four-minute burn zone of high-intensity exercise; the broader strength and anti-aging claims outrun the evidence.
Randomized trials and meta-analyses support alpha-lipoic acid for relieving diabetic-neuropathy symptoms, with 600 mg/day the identified optimal dose — but the four-year NATHAN 1 trial…
Where the evidence lands: ALA is among the better-evidenced supplements for neuropathy symptom relief; disease modification remains unproven, one long trial was null, and a rare autoimmune-hypoglycemia flag exists.
A striking result from one tiny overnight experiment is being sold as a universal brain boost. A newer replication makes the real story more useful—and more modest.
Where the evidence lands: A single high dose of creatine improved one language-processing measure by 29.1% in a 15-person sleep-deprivation experiment, but that was a pooled baseline-adjusted contrast—not a universal boost in thinking. A 29-person replication found smaller 6–12% signals, mostly below its multiple-testing threshold; normal daily cognition and longevity benefits remain unproven.
Broccoli-sprout sulforaphane flips one of biology's master antioxidant switches. Human trials show modest blood-glucose and detoxification effects — biomarker-level wins, not…
Where the evidence lands: Concentrated broccoli-sprout sulforaphane modestly lowers fasting glucose and HbA1c in dysregulated type 2 diabetes and subsets of prediabetes (about 0.2 mmol/L average in a 2025 trial, larger in predicted responders), and enhances carcinogen detoxification — but benefits are biomarker-level, and bioavailability depends on active myrosinase.
Blood ergothioneine falls with age, and low levels track with cognitive decline, cardiovascular disease, frailty, and mortality in observational cohorts — but the human data are almost…
Where the evidence lands: A genuinely intriguing 'longevity vitamin' candidate with striking cohort associations and one small positive pilot trial — but the human benefits remain suggestive rather than established.
Inulin reliably feeds beneficial gut bacteria, eases constipation and nudges metabolic markers in prediabetes and type 2 diabetes — but the average effects are small, the certainty is…
Where the evidence lands: Inulin is a genuinely functional prebiotic fiber — good for stool frequency, gut bacteria and modest glycemic and lipid improvements in the right populations — but it is not a proven treatment or longevity intervention, and bloating is a common, honest trade-off.
Probiotics have genuine randomized-trial support for a handful of specific problems — antibiotic-associated C. difficile diarrhea above all — and a long tail of modest, strain-dependent…
Where the evidence lands: Probiotics are best understood as strain-specific tools: a Cochrane review of 31 trials found they cut the risk of C. difficile-associated diarrhea during antibiotic use from 4.0% to 1.5%, while benefits elsewhere are modest and a head-to-head review found multi-strain blends are not inherently superior to single strains.
Low-dose lithium orotate sits in a peculiar evidence gap: prescription lithium prevents suicide in mood disorders, trace lithium in drinking water correlates with less dementia, and a…
Where the evidence lands: The defensible position: lithium is a biologically active element with striking observational and animal signals at low doses, one proven benefit at prescription doses in psychiatric illness, and zero completed randomized trials of supplement-level lithium orotate for cognition, mood, or aging.
Boswellia serrata extracts reduce osteoarthritis pain and stiffness in multiple randomized trials and meta-analyses, sometimes within days — but many studies are small, industry-sponsored…
Where the evidence lands: Boswellia extract is a plausibly effective, short-term-safe option for osteoarthritis symptoms — with real mechanistic backing — but trial quality issues and poor absorption of boswellic acids mean the specific extract matters and certainty remains limited.
IV NAD sells immediacy; NR and NMN pills have more human data. Both can move biomarkers, but neither has proved longer life.
Where the evidence lands: Oral NR and NMN consistently raise NAD-related biomarkers and occasionally produce population-specific functional signals; direct IV NAD has mainly pharmacokinetic and tolerability data. No route has proved broad rejuvenation or longer human life, and IV delivery adds procedural and product-quality risks.
Oral NMN reliably raises NAD+ in human blood — on that, the trials agree. Whether that rise buys anything a person would notice is, after dozens of small studies, still unresolved.
Where the evidence lands: NMN demonstrably raises blood NAD+ and is generally well tolerated at studied doses, but functional benefits are modest and inconsistent, and no trial has measured lifespan or disease prevention.
Quercetin shows a small blood-pressure effect at higher doses in meta-analyses of randomized trials — but almost everything else claimed for it, including its famous senolytic story, is…
Where the evidence lands: The strongest human evidence is a modest ~2–3 mmHg blood-pressure reduction, mainly at ≥500 mg/day in people with hypertension; the senolytic fame comes from the dasatinib-plus-quercetin drug pairing, not over-the-counter quercetin.
A single organ-support gummy packs lutein, zeaxanthin, nattokinase, inulin, apple cider vinegar, rutin and trehalose. The evidence behind those seven compounds ranges from large randomized…
Where the evidence lands: The ingredients in multi-organ formulas carry wildly uneven human evidence — strongest for lutein and zeaxanthin, weakest for rutin and trehalose — and no trial has tested the combination, so any benefit is an inference, not a finding.
MSM is one of the most-discussed joint supplements on the internet; its human trials are small, short, often industry-funded, and report modest knee pain and quality-of-life benefits of…
Where the evidence lands: Small randomized trials suggest MSM modestly improves knee pain and knee-related quality of life, mostly at 2–6 g/day, and it appears well tolerated up to about 4–6 g/day; the effects are small, some trials found nothing, and a 1,500 mg product sits at the low end of studied doses.
Akkermansia muciniphila improved insulin sensitivity, insulinemia and cholesterol in a landmark human trial — but a larger 2026 multicenter trial missed its primary endpoint, benefits may…
Where the evidence lands: Akkermansia supplementation is safe and metabolically promising in small human trials — especially the pasteurized form — but the largest trial to date was negative overall, so this remains an early-stage, subgroup-dependent intervention, not a proven one.
Meta-analyses of randomized trials find oral PEA reduces chronic pain of mixed origin and is well tolerated — but heterogeneity is very high, study quality is often low, publication bias…
Where the evidence lands: PEA is a promising, well-tolerated adjunct for chronic pain that often takes one to two months to show benefit; it is not a proven stand-alone therapy, and its anti-aging angle remains preclinical.
Urolithin A — a metabolite some gut microbiomes make from pomegranate ellagitannins — stimulates mitophagy and improved muscle strength and endurance in randomized trials of middle-aged…
Where the evidence lands: The defensible claim is narrow: ellagitannin-derived urolithin A modestly improved muscle function in small human trials, pomegranate products modestly lowered blood pressure in meta-analyses, and your own microbiome decides whether the fruit's compounds ever become that molecule.
Apigenin inhibits CD38, the enzyme that drains NAD+ as tissues age — a beautiful mechanism demonstrated in animals and cells. In humans, the molecule has never been tested at supplement…
Where the evidence lands: Apigenin is a pharmacological CD38 inhibitor that raises NAD+ in animal and cell studies, but human evidence comes only from chamomile extracts (which deliver far less apigenin) — whether capsules raise NAD+ or affect aging in people is unproven.
Luteolin reliably calms inflammatory signaling in rodent brains and cultured cells, and small human trials — mostly of luteolin combined with other agents — report intriguing benefits. But…
Where the evidence lands: The defensible bottom line: luteolin has a consistent anti-neuroinflammatory mechanism in preclinical models and promising, indication-specific human signals — most notably for smell recovery after COVID-19 in combination with palmitoylethanolamide — but standalone luteolin failed its placebo-controlled test and remains unproven for human cognitive aging.
L-methylfolate is the already-active form of folate, and trials show it raises folate status and lowers homocysteine at least as well as folic acid — with its best-tested use as an…
Where the evidence lands: L-methylfolate reliably improves folate status and lowers homocysteine, and at 15 mg/day it improved response in SSRI-resistant depression (NNT around 6) — but hard outcomes are mixed, the 7.5 mg dose failed, and longevity uses are extrapolation, not evidence.
Glucosamine and chondroitin are among the most studied joint supplements on earth — and after decades of trials, the honest summary is a draw: possibly useful for some knees, dismissed by…
Where the evidence lands: For painful knee osteoarthritis, the glucosamine–chondroitin combination performed no better than placebo overall in the landmark GAIT trial but matched celecoxib in the MOVES trial; meta-analyses and guidelines remain genuinely split.
Phosphatidylcholine is a structural brick of every cell membrane and the diet's main form of choline — yet its clinical record is a stack of contradictions: a colitis program that soared…
Where the evidence lands: Delayed-release phosphatidylcholine genuinely helped ulcerative colitis patients in randomized trials and a meta-analysis — until two large phase 3 trials failed in 2024 — while the liver, brain, and anti-aging claims rest on small studies, null results, or mechanistic work, not on proven human benefit.
Betaine (trimethylglycine) reliably lowers the amino acid homocysteine in human blood — a real, dose-dependent, well-replicated effect on a lab number. Whether lowering that number…
Where the evidence lands: Oral betaine lowers fasting and post-load homocysteine in a dose-dependent way (about 1.2 µmol/L on average at 4 g/day and above) and a prescription form is FDA-approved for homocystinuria — but homocysteine lowering has never been shown to reduce cardiovascular events, and doses around 4 g/day modestly raise total cholesterol.
Magnesium genuinely lowers blood pressure by a couple of points in pooled trials and shows modest sleep benefits in the sleepless — but most of the research used other salt forms, so the…
Where the evidence lands: Oral magnesium lowers blood pressure about 2 mmHg on average and can modestly improve insomnia, especially in people with low intake — but benefits are small, absent in the already-healthy, and mostly not specific to the glycinate form.
Acetyl-L-carnitine shuttles fat into the cellular furnace and crosses into the brain — and for depression, fatigue in the very old, and maybe diabetic nerve pain, the human trials are…
Where the evidence lands: ALCAR has modest but real trial support for depressive symptoms in older adults, fatigue in the very old, and possibly diabetic neuropathy — but a Cochrane review found no clear cognitive benefit in healthy people, and large modern trials are still missing.
Resveratrol became famous as the red-wine compound that extended lifespan in laboratory organisms. Two decades into human testing, the picture is quieter: modest vascular and…
Where the evidence lands: In people with metabolic or cardiovascular risk, resveratrol at 500 mg/day or more modestly improves endothelial function and inflammation markers — but it has never been shown to prevent heart attacks, dementia, or early death, and its celebrated longevity mechanism remains preclinical.
CoQ10's best human evidence is as an adjunct in chronic heart failure — striking relative-risk reductions still graded low certainty — while migraine prevention has real support and the…
Where the evidence lands: CoQ10 is a promising but low-certainty adjunct in heart failure and has genuine support for migraine prevention; no trial shows it extends life in healthy people, and the statin muscle-pain rationale failed testing.
Creatine monohydrate plus resistance training reliably adds modest lean mass and strength, including in older adults, and modestly improves memory — but the bone benefits are unproven and…
Where the evidence lands: At 3–5 g/day, creatine is among the best-evidenced and best-tolerated supplements for strength and lean mass when paired with resistance training; claims beyond that — bone density, big cognitive effects, benefits without exercise — are weak, inconsistent, or absent.
Behind every beetroot shot is a person watching a blood-pressure reading edge upward with age. The nitrate science is real — about 5 mmHg on average — and the limits are real too.
Where the evidence lands: Beetroot juice and dietary nitrate modestly lower systolic blood pressure (about 5 mmHg on average in hypertension trials) and improve some exercise-capacity measures, but trials are small and short, and no study has tested stroke or heart-attack outcomes.
Grape seed extract pools to a systolic blood-pressure reduction of roughly 2–6 mmHg across meta-analyses — larger in younger, obese, or metabolic-syndrome patients — with inconsistent…
Where the evidence lands: Grape seed extract has a coherent mechanism and a small, real blood-pressure effect in pooled trials — and nothing yet on heart attacks, strokes, or lifespan.
Pycnogenol improves endothelial surrogate markers and trims about 3 mmHg off blood pressure in pooled trials, but a Cochrane review grades nearly all of its outcomes very low certainty,…
Where the evidence lands: Pycnogenol shows mechanistically plausible, small vascular effects on surrogate measures; the certainty is graded at the bottom of the scale and no clinical-outcome trial exists.
Citrus hesperidin improves endothelial function and inflammatory markers in small human trials and trims cholesterol and blood pressure modestly — inconsistently, with variable…
Where the evidence lands: Hesperidin shows suggestive surrogate improvements — better endothelial function, small LDL and TNF-alpha reductions — but pressure effects are inconsistent and no trial has tested heart attacks, strokes, or death.
Astaxanthin, the carotenoid that colors salmon, reliably shifts oxidative-stress biomarkers in human trials — lowering malondialdehyde, raising antioxidant capacity — but no large trial…
Where the evidence lands: Astaxanthin is biologically active as an antioxidant in humans, with modest signals for skin moisture, fatigue, and some joint and inflammatory outcomes; anti-aging claims beyond biomarkers and skin are extrapolations, not findings.
In small randomized trials, saffron extract at roughly 20–30 mg/day reduces mild-to-moderate depressive symptoms and performs comparably to SSRIs with fewer adverse events, and modestly…
Where the evidence lands: Saffron is among the better-supported botanicals for mild mood and sleep complaints, yet the evidence base is small, short-term, partly industry-funded, and not a substitute for prescribed treatment.
L-carnitine ferries fat into mitochondria, and the heart runs on that ferry. Older trials suggest it helps after a heart attack — fewer deaths, less arrhythmia, smaller infarcts — but the…
Where the evidence lands: Meta-analyses of older, mostly small trials associate L-carnitine given around acute myocardial infarction with reduced mortality and ventricular arrhythmias, and a centenarian trial found less fatigue at 2 g/day — but large modern trials are absent, and gut-bacterial conversion to TMAO is a genuine unresolved safety question for everyday supplementation.
Glycine is a building block for collagen, glutathione, creatine and heme, and small trials show 3 grams before bed improves subjective sleep — but the studies are tiny, some are…
Where the evidence lands: About 3 g of glycine at bedtime improves subjective sleep quality in small trials, and glycine-plus-cysteine combinations show intriguing aging-related effects — but the human evidence is early, small-scale and largely unreplicated.
PQQ is a redox-active compound from soil and natto that grows mitochondria in rodent and cell studies — and a handful of small, short, mostly Japanese and manufacturer-linked human trials…
Where the evidence lands: Small human trials of PQQ (roughly 20 mg/day, up to 12 weeks, a few dozen participants) report improved memory, attention, and cognitive flexibility, with one trial raising BDNF and cerebral oxygen saturation — but the celebrated mitochondrial-biogenesis mechanism is cell-and-rodent work, and no large independent human trial or hard clinical endpoint exists.
Observational cohorts tie polyphenol-rich diets to lower mortality, and randomized trials show modest improvements in blood pressure, lipids and glucose — but the big supplement trials…
Where the evidence lands: The strongest evidence favors varied, polyphenol-rich dietary patterns; supplement trials show modest metabolic effects and some nulls, so a mixed polyphenol blend is an inference from the diet literature, not a tested product.
Myo-inositol, a precursor of insulin's second messengers, improved insulin sensitivity and ovulation in PCOS trials and roughly halved gestational-diabetes risk in a low-certainty Cochrane…
Where the evidence lands: For PCOS and gestational-diabetes risk, myo-inositol has real but mixed randomized-trial support and a benign safety profile; it is not proven superior to metformin, and for aging or longevity it is essentially unstudied.
Randomized trials and meta-analyses find MSM produces statistically significant but generally small reductions in joint pain — slower and weaker than NSAIDs, with inconsistent results,…
Where the evidence lands: The fair label claim is 'supports joint comfort': MSM is well tolerated and shows small benefits in some trials, but nothing in the human literature shows it rebuilds cartilage or modifies joint disease.
Lutein and zeaxanthin failed the headline test in the landmark AREDS2 trial, then a decade of follow-up showed they slow progression of macular degeneration and safely replaced a risky…
Where the evidence lands: For people who already have age-related macular degeneration, lutein plus zeaxanthin is among the best-supported supplements in existence — it slows progression to late disease over ten years and safely replaces beta-carotene. It does not prevent the disease in healthy eyes, and the cognition claims are narrow and mixed.
For the person staring at the ceiling at three in the morning, tart cherry extract offers a gentle, food-level hope. Small trials say it may add sleep; better-powered trials say maybe not.…
Where the evidence lands: Small randomized and crossover trials show tart cherry modestly increases sleep time and quality (over an hour of extra objectively measured sleep in one pilot), but recent better-powered trials were null — at best a mild, food-level sleep aid, not a treatment for insomnia.
All-in-one longevity formulas bundle a dozen compounds aimed at the hallmarks of aging. The strongest evidence belongs to individual ingredients — often at doses, and in combinations, that…
Where the evidence lands: No controlled human trial has tested the finished multi-ingredient formula; the evidence is ingredient-level, mostly early-stage, and frequently involves doses far above what a daily sachet delivers.
Carnosine — the muscle dipeptide that buffers acid and traps glycation chemistry — modestly lowered fasting glucose and HbA1c in meta-analyses of randomized trials in prediabetes and type…
Where the evidence lands: Across meta-analyses, carnosine or beta-alanine supplementation modestly improves glycemic markers in people with prediabetes or type 2 diabetes; the trials are small and short, several outcomes were null, and nothing yet shows it changes long-term health outcomes.
Glucosamine and chondroitin — the backbone of Osteo Bi-Flex — have been tested in some of the largest supplement trials ever run. The verdict is genuinely split: a landmark NIH trial found…
Where the evidence lands: For painful knee osteoarthritis, glucosamine plus chondroitin is safe and may modestly ease symptoms — one trial found the combination comparable to celecoxib in severe pain — but the pivotal GAIT trial found no clinically meaningful benefit overall, and the lifespan claims rest on observational data with a documented selection-bias problem.
Milk thistle's extract, silymarin, is the world's default herbal answer to a frightening diagnosis: fatty liver. Meta-analyses show it modestly improves liver enzymes and metabolic markers…
Where the evidence lands: Silymarin modestly lowers ALT and AST and improves cholesterol, triglycerides and fasting insulin in pooled NAFLD trials — but a rigorous biopsy-based NASH trial missed its primary endpoint (with only a fibrosis signal: 22.4% vs 6.0% over placebo), a landmark cirrhosis trial found no survival benefit, and nothing shows it prevents cirrhosis or liver-related death.
Standardized olive leaf extract shows modest, repeatable blood-pressure reductions in people with prehypertension and hypertension, plus small lipid effects — but trials are small,…
Where the evidence lands: Olive leaf extract's best human evidence is a modest blood-pressure-lowering effect in people with elevated readings, with small cholesterol and triglyceride improvements and two positive knee-pain trials — real but adjunctive-scale effects, limited by small samples and inconsistent extract quality.
Zinc anchors supplement stacks and cold-season rituals alike. The trial record says: a modest, contested shortening of colds, a real role in one landmark eye trial, and no proof for…
Where the evidence lands: Oral zinc started soon after symptom onset can modestly shorten colds (with low-certainty evidence), and high-dose zinc helped slow macular degeneration progression in the AREDS trial — but prevention is unproven and chronic high doses carry a copper-deficiency risk.
Vinegar can blunt some post-meal glucose responses, but the weight-loss evidence is small, heterogeneous, and weakened by a prominent retraction.
Where the evidence lands: The best-supported vinegar effect is a modest change in some post-meal glucose responses. Durable weight loss and disease prevention remain unproven, especially after a prominent weight-loss paper was retracted.
DHEA levels decline with age, but randomized reviews do not show broad restoration of strength, cognition, function, or lifespan from supplementation.
Where the evidence lands: An age-related fall in DHEA does not prove a deficiency syndrome. Trials show limited, outcome-specific effects rather than whole-body rejuvenation or longer life.
Linoleic acid is often described online as inflammatory or toxic. Controlled feeding trials and clinical outcome data do not support that blanket claim.
Where the evidence lands: Mechanistic concerns about omega-6 fats do not translate into evidence that ordinary seed-oil intake causes systemic inflammation. Food quality, cooking, dose, and what the oil replaces matter more than the viral label.
A small 2009 rugby study raised DHT concerns without measuring hair. A 2025 randomized trial measured follicles directly and found no significant difference.
Where the evidence lands: The hair-loss claim was inferred from DHT, not observed hair loss. A direct 2025 randomized trial found no significant follicular harm, although very long-term effects cannot be ruled out completely.
A large UK Biobank study linked glucosamine use with lower mortality. A later methods paper showed how selection alone could create nearly the same effect.
Where the evidence lands: Glucosamine use is associated with lower mortality in large cohorts, but prevalent-user and healthy-participant selection can reproduce an effect of similar size. Randomized glucosamine trials address osteoarthritis symptoms, not lifespan.
Molecular hydrogen has plausible signaling effects and small metabolic trials. The evidence does not show detoxification, disease prevention, or longer life.
Where the evidence lands: Small trials suggest possible biomarker effects from measured hydrogen exposure, but no clinical evidence establishes disease prevention or longevity. Consumer products may not reproduce studied doses.
One human infusion pilot mapped metabolism during a six-hour drip. It did not show better energy, cognition, addiction recovery, or slower aging.
Where the evidence lands: A small infusion study showed that IV NAD+ is extensively metabolized. It did not prove better energy, cognition, recovery, or slower aging, and controlled efficacy trials are still missing.
Several pilot trials report cognitive signals, but samples are small, products differ, follow-up is short, and dementia prevention has not been shown.
Where the evidence lands: Small trials provide preliminary cognitive signals for some lion’s mane preparations. They do not establish brain regeneration or dementia prevention, and product standardization remains a major gap.
Animal work suggests brain penetration, but human cognition trials are small, often use combination formulas, and do not establish dementia prevention.
Where the evidence lands: Rodent brain-magnesium findings are not proof of human cognitive rejuvenation. Small and often multi-ingredient trials are interesting, but larger independent studies are needed.
Melatonin can help selected sleep and circadian problems, but high-dose longevity claims rely heavily on mechanisms and animal research rather than human outcomes.
Where the evidence lands: Melatonin has indication-specific sleep evidence, not human longevity evidence. High-dose anti-aging claims extrapolate from mechanisms and animal work, while long-term safety remains incompletely defined.
Correcting deficiency and taking high-dose vitamin D are different interventions. Large trials have not shown broad cancer or cardiovascular prevention, and bolus dosing can increase falls.
Where the evidence lands: Treating vitamin D deficiency is not the same as using high doses for longevity. Large randomized trials are neutral for major prevention outcomes, and bolus dosing has increased falls in older adults.
COSMOS found modest cognitive benefits in older adults, while three large cohorts found no mortality advantage. Neither result makes a multivitamin a substitute for diet or care.
Where the evidence lands: COSMOS supports a modest average cognitive benefit in older adults, while large cohorts show no mortality advantage. A multivitamin may fill gaps but is not a proven dementia-prevention or longevity treatment.
A plant alkaloid with real metabolic effects, an AMPK mechanism, and a marketing problem.
Where the evidence lands: Berberine has credible AMPK-driven effects on blood sugar and cholesterol in randomized trials of varying quality, but it is not a weight-loss drug and carries real GI side effects and CYP/P-gp drug interactions.
One of the most studied supplements helps preserve muscle and may aid memory in older adults, but the muscle benefit depends largely on pairing it with resistance exercise.
Where the evidence lands: Creatine monohydrate is safe and reliably boosts muscle and strength gains in older adults when paired with resistance training, with modest emerging benefits for memory but little effect on bone.
Small trials reported sweeping benefits; a larger independent trial missed its main glutathione target.
Where the evidence lands: GlyNAC rests on a plausible glutathione-restoration idea and looks safe, but the sweeping benefits come from very small single-group trials, while the largest independent trial missed its primary glutathione endpoint except in a low-baseline subgroup.
Both raise blood NAD+ in randomized trials, but the clinical payoff remains modest and unproven, and one of them sits in regulatory limbo in the US.
Where the evidence lands: NMN and NR both dependably raise blood NAD+ in randomized human trials, but proven health benefits in people remain modest and unsettled.
Fish-oil fats nudged biological-aging clocks in one trial, but the heart-disease record is genuinely mixed.
Where the evidence lands: Omega-3 slightly slowed biological-aging clocks in one trial, but its effect on actual heart-disease outcomes ranges from clear (high-dose EPA in high-risk patients) to nonexistent (general prevention), so it is promising, not proven.
Broccoli-sprout sulforaphane switches on the cell's antioxidant defense system, but the human trials range from encouraging to flatly null.
Where the evidence lands: Sulforaphane convincingly switches on the Nrf2 detox pathway, but human outcomes are mixed, some trials are null, and absorption depends heavily on preparation.
A 2023 Science paper showed taurine extends healthy lifespan in mice and monkeys, but the human evidence is still observational, not causal.
Where the evidence lands: Taurine extended healthy lifespan in mice and monkeys and declines with age in humans, but the human data are only correlational, so its anti-aging benefit in people remains unproven pending clinical trials.
A gut-derived metabolite that switches on mitochondrial cleanup has real human data, including trials that missed their main goals.
Where the evidence lands: Urolithin A reliably shifts mitochondrial biomarkers and appears safe, but two of its randomized trials missed their primary strength and walking-distance endpoints, so functional benefits remain unproven.
Evidence suggests spermidine may support healthy aging, but human data is still emerging.
Where the evidence lands: Spermidine shows promise for longevity based on lab and animal studies, with preliminary human evidence suggesting possible benefits, but more research is needed to confirm effects.
A look at the research behind NMN supplementation for healthspan and longevity.
Where the evidence lands: The available evidence suggests NMN supplementation can increase NAD⁺ levels and may offer some benefits for certain aspects of healthspan, but more research is needed to confirm its effects on longevity.
Fisetin, a flavonol, shows promise as a senolytic agent, but human longevity benefits remain to be demonstrated.
Where the evidence lands: Fisetin shows early promise as a senolytic in lab studies, but human longevity benefits remain unproven—more research is needed.
A critical look at the evidence behind Magellan NAD⁺ Activation Capsules.
Where the evidence lands: Magellan NAD⁺ Activation Capsules combine ingredients with some promising but preliminary evidence in animals and limited human data; realistic expectations should be cautious until more robust clinical trials are available.
Learn what the evidence says about key ingredients in this all-in-one longevity formulation.
Where the evidence lands: The ingredients in NOVOS Core have shown promise in laboratory studies for supporting pathways linked to aging, but human data on lifespan or healthspan extension is limited.
24 articles · topic hub →
In the 204-person LEAP trial, eight weeks of load-management education plus hip-abductor exercise left 77.3% of people with gluteal tendinopathy rating themselves at least moderately…
The Achilles complaint that ends running seasons turned out not to be an inflammation at all, which may help explain why rest and anti-inflammatories so often disappoint. What has held up…
Where the evidence lands: Chronically painful tendons show no inflammatory cells on histology (the basis for renaming tendinitis as tendinopathy), which helps explain why rest and anti-inflammatories underperform. The loading evidence: Alfredson's prospective 1998 study returned all 15 athletes to full running after 12 weeks of heavy eccentric calf training while all 15 conventionally treated comparisons went to surgery (nonrandomized comparison); Beyer's RCT (58 patients) found eccentric and heavy slow resistance training equally effective at 52 weeks with higher compliance under HSR (92% vs 78%); Kongsgaard's patellar RCT (39 men) found cortisone's 12-week benefit deteriorated by half-year while both loading programs held, with HSR elevating collagen turnover. Silbernagel's RCT (38 patients) demonstrated no negative effects from continued running under a pain-monitoring model versus 6 weeks of rest (57→85 vs 57→91 on the VISA-A-S score, no significant difference), and her 5-year case series found 80% fully recovered on exercise alone, with fear of movement inversely correlated with heel-rise work recovery (−0.590). De Vos's double-blind JAMA trial found PRP no better than saline (+21.7 vs +20.5 points; difference 0.9, CI excluding the predefined 12-point margin) with eccentrics in both arms. Risk-factor evidence is limited and high-bias: nine factors with limited support (including quinolones, alcohol, plantar-flexor weakness); twenty-six with none, including body weight, foot posture and activity level.
Creatine's muscle evidence in adults over 50 comes entirely from trials where everyone was lifting, and dietary nitrate's dose-response study found 4.2 mmol did nothing while 8.4 mmol…
Where the evidence lands: Creatine monohydrate at 3-5 g daily and roughly 400 mg of dietary nitrate are each well evidenced on their own, but creatine's benefit in older adults is inseparable from resistance training and nitrate's benefit is time-dependent, peaking two to three hours after it is swallowed. Buy nitrate by the printed milligram, keep antibacterial mouthwash away from it, and treat the combination as reasonable rather than proven: no randomized trial has tested the two together.
In the SWAN cohort, LDL and apolipoprotein B jump, and arterial stiffening accelerates from 0.9 to 7.5 percent a year, specifically in the year on either side of the final menstrual…
Where the evidence lands: In SWAN's piecewise analyses, only total cholesterol, LDL and apolipoprotein B jumped within the year around the final menstrual period (1,054 women; pattern consistent across ethnic groups), while glucose, insulin, blood pressure, fibrinogen and CRP tracked chronological age — and carotid-femoral pulse-wave velocity accelerated from 0.9 to 7.5 percent per year in that same window before flattening (339 women). Earlier menopause carries a graded, observational risk ladder for a first non-fatal cardiovascular event versus menopause at 50–51: HR 1.55 before age 40, 1.30 at 40–44, 1.12 at 45–49, strongest before age 60 and persisting in never smokers (301,438 pooled women); a separate 310,329-woman meta-analysis puts menopause before 45 at RR 1.50 for coronary disease and 1.12 for all-cause mortality. The hormone trials ended in a precise place: WHI's estrogen+progestin arm was stopped early (absolute harms of roughly 7–8 excess events per 10,000 person-years each for CHD, stroke, pulmonary embolism and breast cancer), the 13-year overview found estrogen-alone more favorable in women who started in their 50s (19 fewer global-index events per 10,000 women annually, vs 51 excess at 70–79) with no effect on all-cause mortality for either regimen, and ELITE showed estradiol slowing carotid intima-media thickening only when started within 6 years of menopause — a surrogate, not events, with cardiac CT (calcium, stenosis, plaque) null in both strata. Trial investigators' own bottom line: not for chronic-disease prevention, appropriate for symptom management in some women — which is a clinician-level decision.
Home monitoring earns its effect only when the readings feed decisions; on its own it moved pressure a statistically meaningless 1 mm Hg. What does move the number, in randomized trials:…
Where the evidence lands: In randomized trials, blood-pressure self-monitoring lowered systolic pressure only when the readings drove treatment decisions (−3.5 to −4.7 mm Hg in TASMINH4; −6.1 with intensive support in pooled data) — monitoring alone moved it a non-significant 1.0 mm Hg. The DASH eating pattern lowered systolic pressure 5.5 mm Hg overall and 11.4 mm Hg in hypertensives with sodium and weight held constant, and adding low sodium widened the gap versus a typical high-sodium American diet to 7.1 mm Hg in those without hypertension and 11.5 in those with it. Increased potassium cut systolic pressure 3.49 mm Hg overall, with the effect seen only in those with hypertension. A 270-trial network meta-analysis ranked isometric exercise (−8.24 mm Hg) above aerobic, resistance and interval training, with the wall squat the top submode. Weight loss returned roughly 1 mm Hg per kilogram. SPRINT showed why the number matters: a sustained ~15-point separation produced 25 percent fewer major cardiovascular events and 27 percent lower all-cause mortality, alongside more hypotension, syncope, electrolyte and kidney adverse events — target-setting belongs with a clinician.
Zone 2 is a naming convention, not a physiological constant, and most of the evidence behind it comes from trained endurance athletes. What the polarized-training trials, the HIIT…
Where the evidence lands: Zone 2 means low-intensity work below the lactate threshold, but the label shifts between zone systems: in the polarized-training literature, zone 2 is the between-thresholds band that model deliberately minimises to 3–5% of training time. Identification is imprecise — six lactate-threshold methods applied to one dataset of elite skiers showed no agreement at a ±0.5 mM criterion. Polarized training beat other distributions for VO₂peak by SMD 0.24 (95% CI 0.01–0.48), only in trials under 12 weeks and only in highly trained athletes, with no advantage for time trial (SMD −0.01), time to exhaustion or threshold speed. In 30 recreational runners, 10 km improvement was 5.0% vs 3.6%, not significant. Head-to-head for VO₂max, interval training leads continuous training by about 1.2 mL·kg⁻¹·min⁻¹ in healthy adults aged 18 to 45 and 1.74 in older adults; in women the difference was null. A PGC-1α meta-analysis found large effects for both interval (g = 1.29) and continuous (g = 1.01) training, with no significant difference between them, in a pooled estimate with substantial heterogeneity. The longevity evidence — HR 0.47 for high vs low fitness, HR 0.53 at 7,000 steps — is entirely observational and assigned no one an intensity.
At least one in three adults over 65 falls each year, and the trials are unusually clear about what helps. Balance-specific exercise cuts the fall rate by about a quarter, tai ji quan beat…
Where the evidence lands: Balance and functional exercise reduces the rate of falls by 24 percent in high-certainty Cochrane evidence (34 percent, at moderate certainty, when combined with resistance training), and a tailored tai ji quan program cut the fall rate 58 percent versus stretching and 31 percent versus multimodal exercise in a 670-person head-to-head trial. Home fall-hazard reduction cuts falls 38 percent in people at elevated risk but showed no benefit in unselected people. Common prescriptions carry some of the largest risk multipliers in observational data (SSRIs OR 2.02, opioids 1.60, polypharmacy 1.75) — one reason geriatric practice emphasizes regular medication review; expedited first-eye cataract surgery reduced the rate of falling 34 percent in a randomized trial; an annual 500,000 IU vitamin D dose increased falls 15 percent and fractures 26 percent. Gait speed plus age and sex predicts survival about as well as multi-factor risk models — and you can measure it yourself.
Aerobic capacity falls faster with every decade, in people who exercise as well as those who do not — yet controlled trials raise the number in older adults by a few mL/kg/min. Five years…
Where the evidence lands: The decline is real and it accelerates: in the Baltimore cohort it ran from 3%-6% per 10 years in the 20s and 30s to more than 20% per 10 years in the 70s and beyond, in every activity quartile. Training has not been shown to flatten that slope; trained men are measured higher at every age, but only controlled trials speak to what training does to an individual. Pooled trials in sedentary older adults show a net VO2max gain of 3.78 mL/kg/min, largest at 66%-73% of heart rate reserve, 40-50 minutes, 3-4 days a week; head-to-head, intervals came out ahead by 1-2 mL/kg/min. Fitness-mortality findings are associations, and non-response is real.
Most night workers’ clocks never fully adapt, and the trials show they do not need to. Timed light and darkness, a fixed sleep anchor, a short nap, early caffeine and daytime meals…
Where the evidence lands: Fewer than 3% of permanent night workers fully adapt their body clock, but partial realignment is enough to bring night-shift alertness and performance close to daytime levels, and it comes from bright light on the shift, dark glasses on the commute, a fixed dark sleep window, and a 30-minute nap. Melatonin adds about 24 minutes of daytime sleep with no dose-response from 1 to 10 mg; caffeine six hours before sleep still shortens it; eating at night impaired glucose tolerance in three laboratory studies. The long-term cardiovascular and diabetes associations are modest and appear after about five years of exposure.
Lean mass can fall during semaglutide or tirzepatide treatment, but a DXA number is not muscle function—and direct preservation trials are just beginning.
Where the evidence lands: GLP-1-based treatment usually removes much more fat than lean tissue, but absolute lean mass can decline. Track strength and physical function—not DXA alone—and treat exercise and adequate nutrition as important care components whose precise protective effects during semaglutide or tirzepatide therapy are still under study.
A viral longevity lesson says to sleep earlier. The stronger—and less glamorous—case is to protect enough sleep on a schedule your body can keep.
Where the evidence lands: Sleep regularity predicts mortality more strongly than duration in large observational cohorts, but it has not been shown to extend life. Aim for enough sleep and a sustainable schedule; an earlier bedtime is not universally better.
The NMN + resveratrol + pterostilbene stack pairs an NAD+ precursor with sirtuin activators to echo caloric-restriction biology — a coherent rationale built mostly from mechanism and mouse…
Where the evidence lands: The design logic is scientifically literate — fuel NAD+, activate SIRT1 — but the combined stack is untested in humans, and resveratrol's caloric-restriction-mimetic potential appears limited even in mice.
Social media has collapsed careful dose reduction, intermittent maintenance, and unapproved compounded ‘microdoses’ into one seductive idea. Human trials support ongoing treatment for…
Where the evidence lands: Evidence supports ongoing GLP-1 treatment for many people with obesity and suggests that supervised dose reduction can sometimes preserve weight loss. It does not show that tiny compounded doses benefit healthy-weight adults, reduce generalized inflammation, or extend human life.
Mortality benefits begin well below 10,000 steps and the curve often flattens with age. More movement helps, but the exact target is not magic.
Where the evidence lands: Health benefits begin below 10,000 steps and often flatten around 6,000-8,000 in older adults. The best target is a safe, sustainable increase from baseline, not a magic threshold.
Coffee drinkers often have lower mortality in cohorts, including decaf drinkers. Mendelian-randomization results are less decisive, keeping causality and optimal dose uncertain.
Where the evidence lands: Coffee has one of nutrition epidemiology's more consistent favorable associations, but observational evidence does not prove that starting coffee extends life. Tolerance, sleep, preparation, and individual risk still matter.
Short-lived cognitive complaints have been reported, but randomized and observational syntheses do not show that statins cause dementia; some cohorts associate treatment with lower risk.
Where the evidence lands: Statins have not been shown to cause dementia. Population evidence is neutral to reassuring, although new individual symptoms should be evaluated rather than dismissed.
Mouse regeneration experiments and small chemotherapy studies became a universal fasting prescription. Human immune rejuvenation has not been demonstrated.
Where the evidence lands: Prolonged fasting affects nutrient-sensing pathways, but no human trial establishes that 72 hours resets immunity or comprehensively clears damaged cells. The claim is an extrapolation from animal and early translational work.
Sleep-duration studies show a U-shaped mortality curve, but long sleep can be a marker of illness and self-reports cannot define one ideal number for everyone.
Where the evidence lands: Sleep and mortality form a U-shaped observational association, not a precise causal prescription. Quality, regularity, symptoms, and individual need matter alongside duration.
Older cohorts suggested protection, but abstainer bias and genetic studies weaken the causal story. Starting to drink is not a longevity strategy.
Where the evidence lands: The classic alcohol J-curve is vulnerable to former-drinker and healthy-user bias. Genetic studies do not support starting alcohol for cardiovascular protection or longevity.
Self-reported success stories and nutrient calculations cannot establish long-term safety, cardiovascular effects, or lifespan benefit from an all-animal-food diet.
Where the evidence lands: No trial shows that a carnivore diet extends life or prevents chronic disease. Short-term symptom reports are hypothesis-generating, while long-term safety and cardiovascular effects remain unanswered.
Three mechanisms drive the afternoon crash, and only one of them answers to more coffee. An evidence-graded day structure for knowledge workers.
Where the evidence lands: Your afternoon crash is at least three separate problems: attention degrading within a long task, sleep pressure building through the day, and any actual sleep deficit you are carrying. Build the day around that, keep caffeine deliberate and well clear of the hours before bed, and treat naps, light and movement as small helps rather than fixes. Nothing in the supplement aisle in this evidence set beats the schedule itself. If two weeks of a fixed structure changes nothing, stop optimizing and get assessed.
You bought the chair and the standing desk and it still aches. Here is what has trial support in office workers, and what is a waste of money.
Where the evidence lands: The link between sitting and back pain is real but modest and almost entirely cross-sectional, which is why buying furniture did not fix your neck. What has trial support in office workers is unglamorous: about ten minutes of high-intensity neck and shoulder resistance work on most days, walking accumulated toward a real weekly total, and enough consistency to hit roughly seven sessions in ten for three months. Skip the early scan unless you have red flags, and treat saddle numbness or any new bladder or bowel change as an emergency department visit today, not a wait-and-see.
What the loading trials actually show about rebuilding a cranky Achilles, patellar tendon, knee or shoulder after 45, and how long it really takes.
Where the evidence lands: Tendon responds to heavy, slow, progressive load, and it still responds after 50, but on a timescale of months rather than weeks. Pick one loading exercise, run it three times a week, judge it by how you feel the next morning, and give it 12 weeks before you judge it at all. Isometrics and blood flow restriction cuffs are useful tools for keeping you loading when pain or joint tolerance gets in the way, and no supplement in this literature outperforms the training itself.
What the trials actually show about heavy training, protein, supplements and broken sleep in midlife, including the ones that found nothing.
Where the evidence lands: Heavy, supervised, technique-first resistance training around three times a week is the intervention with the best evidence for bone density, strength and function in the postmenopausal women these trials studied, and no supplement in this evidence base replaces it, though none of those trials measured fractures, which is what makes a treatment-range scan a clinician conversation rather than a training problem. Protein and creatine are small modifiers around that training, and calcium or vitamin D supplements did not prevent fractures in the largest pooled analysis of adults not being treated for osteoporosis. Sleep improves with a structured cognitive behavioral program rather than a schedule tweak, and feeling too hot at night is worth treating as a primary variable. Anything here about hormone therapy is reporting from the review papers, not a recommendation.
21 articles · topic hub → · shop this category →
Verbatim local searches for cold plunge, red light, hyperbaric oxygen and PEMF, answered with the trials that exist — what was measured, in whom, over how many sessions, and where the…
PEMF, red light, cold plunges, infrared saunas, hyperbaric oxygen, vibration plates, compression boots and grounding mats, judged against the trials that exist — what was measured, in…
Where the evidence lands: Sham-controlled evidence is the dividing line, and few devices have it. PEMF has repeated placebo-controlled trials in osteoarthritis, but the meta-analyses conflict: one pooled a pain effect of SMD 1.06, one found relief only in knee and hand osteoarthritis, and a 2026 pooling of nine trials in 457 patients found subjective gains with no improvement in objective function. Red light has the strongest efficacy data here — axial elongation of 0.13 mm versus 0.38 mm at 12 months in 264 myopic children — alongside a retrospective cohort reporting reduced cone density in treated children, which cannot show cause. Cold water eases self-reported soreness in physically active people and, used routinely after lifting, blunted type II fibre growth over 7 to 12 weeks. Sauna's 0.37 hazard ratio for sudden cardiac death is observational, Finnish and about hot-air saunas; randomised passive-heating trials moved little, including systolic pressure overall. Hyperbaric oxygen raised telomere length in isolated blood cells by over 20% in an uncontrolled trial of 35 adults aged 64 and older. Vibration plates moved total-femur bone density by g = 0.28 in adults over 55, on low-certainty evidence, with no significant effect at the femoral neck or lumbar spine. Grounding rests on one 16-person trial with questionnaire outcomes.
The viral number comes from a Finnish cohort that measured fatal coronary disease, not a trial that prevented heart attacks. The heat-shock-protein story is plausible biology—not proof of…
Where the evidence lands: Frequent sauna use is associated with lower fatal coronary-disease risk in Finnish cohorts, but no trial shows that sauna prevents heart attacks by 51 percent. Human intervention evidence is small, short, mixed, and limited to risk markers.
Neuromuscular electrical stimulation can preserve and rebuild muscle when ordinary training is impossible — in ICU beds, after surgery, in older adults who cannot lift — but its effects…
Where the evidence lands: EMS has legitimate, trial-backed value for preventing muscle loss during immobilization and illness and for building strength in people unable to do conventional resistance training — but it is a rehabilitation modality, not a shortcut past exercise, and it is contraindicated with pacemakers and over the neck, pregnant abdomen, or broken skin.
Percussive massage guns reliably loosen joints and blunt next-day soreness in controlled trials — and just as reliably fail to boost strength, jump height, or any aging-related outcome.…
Where the evidence lands: Systematic reviews and randomized trials support percussive massage for acutely increasing range of motion without reducing strength, and for reducing muscle stiffness and soreness after fatiguing exercise — but it is often no better than rest, stretching or foam rolling, it can transiently reduce explosive performance if used right before activity, and nothing links it to aging-related outcomes.
The spiked mat is wellness social media's favorite torture device. The underlying technique — acupressure — has real trial support for pain and sleep; the mat itself has one controlled…
Where the evidence lands: Randomized trials and meta-analyses support acupressure itself for modest improvements in back and knee pain, sleep, fatigue, and anxiety — but the one controlled trial of the physical spike mat found it lowered stress no more than lying down, with no change in blood pressure, heart rate, or pain thresholds.
Whole-body vibration produces real, modest gains in leg strength, balance and everyday function in older and deconditioned adults — but the bone-density picture is genuinely mixed, optimal…
Where the evidence lands: Vibration plates are a legitimate low-effort option for improving strength, balance and function in older or mobility-limited people, but they are not a substitute for conventional exercise and most marketing claims outrun the trials.
Weighted blankets deliver deep pressure stimulation, and randomized trials show modest, real reductions in anxiety and self-reported insomnia — strongest in adults with psychiatric…
Where the evidence lands: Weighted blankets are a safe, low-risk comfort aid with modest trial support for anxiety and insomnia severity — one well-designed trial in psychiatric patients showed a large, 12-month-durable effect — but evidence is mixed for objectively measured sleep, absent for sleep duration in children with autism, and the hypothesized oxytocin-cortisol calming pathway was not confirmed.
Foam rolling is gym-bag gospel for recovery and flexibility. The trial record mostly agrees on soreness and range of motion — and mostly shrugs at strength, power, and anything grander.
Where the evidence lands: Foam rolling acutely increases range of motion comparably to static stretching and moderately reduces delayed-onset muscle soreness 24–48 hours post-exercise (a 2024 meta-analysis of 16 RCTs, n=515, found SMD −0.53 to −0.77), but effects on strength, power, and jump performance are trivial or inconsistent.
Pulsed electromagnetic field therapy is real, regulated medicine in one narrow orthopedic niche — fracture non-union — and a sprawling wellness claim everywhere else. The osteoarthritis…
Where the evidence lands: Clinical-grade PEMF raised fracture union rates to about 80% versus 64% with standard care in a 22-trial meta-analysis (certainty still rated low), and osteoarthritis meta-analyses report short-term pain and function benefits that some high-quality reviews cannot separate from placebo — while a systematic review of whole-body wellness mats concluded the evidence for their therapeutic effects is insufficient.
Intermittent pneumatic compression is proven hospital medicine — it prevents deadly clots and helps diseased legs walk farther. The athletic 'recovery' version of the same squeeze is a…
Where the evidence lands: Meta-analyses show intermittent pneumatic compression significantly lowers the risk of deep-vein thrombosis and pulmonary embolism in hospitalized patients and improves walking distance in claudication — but a 2024 systematic review of athletic recovery found only trivial-to-small benefits, mainly reduced perceived soreness, with several trials showing no effect on muscle-damage markers.
Curcumin, the pigment of turmeric, reliably lowers some inflammatory markers in meta-analyses and shows real symptomatic benefit in osteoarthritis — but results are inconsistent, trials…
Where the evidence lands: Curcumin supplementation lowers CRP, IL-6 and TNF-alpha on average and eases osteoarthritis symptoms in meta-analyses, but the evidence is heterogeneous, some analyses are null, and high-bioavailability formulations carry a documented liver-injury caution.
Breathing is the last thing most people think to train — until a climbing blood-pressure reading makes the body's quietest muscles suddenly matter. Six weeks of high-resistance breathing…
Where the evidence lands: High-resistance inspiratory muscle strength training (about 30 breaths a day) lowered systolic blood pressure by roughly 9 mmHg in six-week sham-controlled trials in midlife and older adults, with meta-analyses reporting 8–13 mmHg — but samples are small, follow-up is short, and hard outcomes like stroke are untested.
The peptide is promoted online for tendon, ligament, muscle, bone, and gut healing. Nearly all of that confidence still comes from animals, not controlled human trials.
Where the evidence lands: BPC-157 has an extensive animal literature but almost no controlled human evidence. The only musculoskeletal clinical report was a small uncontrolled retrospective series, and systematic reviewers found no clinical safety data.
A small uncontrolled telomere study and a healthy-aging cognitive trial are intriguing. Neither proves whole-body age reversal or longer life.
Where the evidence lands: HBOT studies report intriguing cognitive and blood-cell biomarker changes. Small samples and surrogate endpoints do not establish age reversal, disease prevention, or longer life.
A small one-hour immersion experiment measured dopamine in blood. It did not demonstrate a 250% rise in brain dopamine, a day-long motivation boost, or the absence of a crash.
Where the evidence lands: The 250% figure came from plasma dopamine during one hour of 14-degree-Celsius immersion. The study did not measure brain dopamine, motivation, or a caffeine-like crash, and broader reviews have not established a universal mood benefit.
Small studies in selected mouth-breathers do not justify universal taping, especially when nasal obstruction or sleep apnea has not been evaluated.
Where the evidence lands: Small studies do not validate mouth taping for everyone who snores. Nasal obstruction and sleep apnea must be considered because closing the mouth can conceal rather than solve the cause.
Transcranial photobiomodulation has small cognitive trials and a growing systematic review literature. Device dose, replication, and clinical meaning remain unsettled.
Where the evidence lands: Small red-light brain trials are promising, but device protocols differ and no study establishes dementia prevention or longer life. Evidence is emerging, not settled.
Evidence shows balance and strength training improves key healthspan markers in older adults.
Where the evidence lands: Balance and strength training has been shown to reduce falls and improve mobility in older adults, but results may vary by individual.
Evidence suggests blood flow restriction training effectively increases muscle strength and mass in older individuals using light exercise loads.
Where the evidence lands: Blood Flow Restriction Cuffs show promise for maintaining muscle strength and mass in older adults using light loads, but evidence directly linking this to longevity outcomes remains limited.
A look at the evidence for sauna, cold plunge, and red-light therapy in promoting longevity and healthspan.
Where the evidence lands: The sauna element has strong evidence for longevity benefits, while cold plunge and red light show preliminary promise but need more research to confirm healthspan effects.
15 articles · topic hub → · shop this category →
RO systems like SimPure demonstrably reduce contaminants linked to serious diseases, but they are not longevity elixirs.
Ambulatory blood pressure — especially nighttime and 24-hour averages — predicts death and cardiovascular events more strongly than clinic readings, unmasking hidden risk; but no…
Where the evidence lands: Out-of-office, 24-hour blood pressure is the reference standard and the stronger predictor of risk — guidelines already say to confirm diagnoses with it — but the device is a lens, not a treatment.
Bright light therapy is an established first-line treatment for seasonal depression, and meta-analyses now show meaningful effects as an adjunct in nonseasonal depression too — roughly…
Where the evidence lands: Thirty minutes of 10,000-lux light each morning is among the best-evidenced non-drug treatments for seasonal affective disorder and a legitimate adjunct in nonseasonal depression — but the trials are small and heterogeneous, blue-light variants remain unproven, and anyone with bipolar-spectrum illness should involve a clinician first.
HEPA filtration demonstrably cuts indoor PM2.5 and nudges blood pressure down by a few millimeters of mercury in randomized trials — while the activated-carbon stage that traps gases rests…
Where the evidence lands: Indoor HEPA filtration produces real exposure reductions and modest, low-certainty cardiovascular benefits — about 2–4 mm Hg systolic — while gas-phase carbon filtration, though mechanistically sound, lacks human-outcome trials of its own.
Research links indoor air that's too dry to impaired airway defense and better viral survival, and air that's too wet to mold and mites — with several reviews converging on 40–60% relative…
Where the evidence lands: Keeping indoor humidity near 40–60% is supported by reviews, lab studies, and a multinational COVID-19 analysis as favorable for airway defense and viral control — but a Cochrane review found only low-certainty benefit from humidification, ventilation may matter more, and no study has tested whether owning a monitor changes any health outcome.
Trihalomethanes and other disinfection by-products are absorbed through skin and lungs during hot showers, and epidemiology links high exposure to elevated bladder-cancer risk — but the…
Where the evidence lands: The exposure pathway is well documented and the cancer association is real but not proven causal; filtration plausibly lowers exposure while proven risk reduction remains undemonstrated.
Evening blue light genuinely suppresses melatonin, but the best-controlled evidence — a Cochrane review of 17 randomized trials — finds blue-light filtering lenses probably do not reduce…
Where the evidence lands: The light–sleep mechanism is real, but the product category's average benefit is not; dimming evening light has a sounder footing than clear-tint lenses, and daytime blocking may even cost alertness.
Fine particulate matter is one of the most consistently documented environmental risks to human life, and consumer laser sensors can now count it in real time. The evidence for the…
Where the evidence lands: Cutting PM2.5 exposure is backed by large cohorts and randomized purifier trials, and validated consumer sensors are accurate enough to guide behavior — in one multi-centre trial, monitoring with feedback led two-thirds of households to cut indoor levels by a median of about 19%. No trial yet shows that owning a monitor itself improves health outcomes.
Controlled experiments link indoor CO2 levels of 1,000–2,500 ppm to lower decision-making scores, but dissenting studies and co-pollutant confounding keep the molecule's direct role…
Where the evidence lands: Under-ventilated air probably costs you some cognition and sleep quality; a CO2 monitor is a useful proxy for that — but only if you act on the readings.
Nighttime traffic noise is a documented cardiovascular risk factor, and white-noise masking genuinely helps some sleepers in loud settings. But the most rigorous review graded the evidence…
Where the evidence lands: Chronic nighttime transportation noise is linked to higher blood pressure and ischemic heart disease, and a 2025 meta-analysis of 12 randomized trials found white noise improved subjective sleep quality in adults — yet the evidence quality is very low, one experiment found earplugs outperformed masking against traffic noise, and masking is best reserved for genuinely noisy settings at low volume.
Reverse osmosis removes a documented list of contaminants linked, mostly observationally, to cancer and cardiovascular disease. What no study has shown is that installing one under your…
Where the evidence lands: Reverse osmosis is genuine, broad-spectrum exposure reduction — one to two orders of magnitude — against contaminants with real, mostly observational disease links; it is not a proven health intervention, and its value depends entirely on what your local water actually contains.
Wrist-worn pulse oximeters can measure blood oxygen with surprising accuracy — one model came within about 1 percent of arterial blood-gas analysis — and the nocturnal hypoxia they track…
Where the evidence lands: Overnight oxygen desaturation — the 'hypoxic burden' — is a validated predictor of cardiovascular events and mortality, and good wearable oximeters can track it, though some consumer devices fail accuracy thresholds and reflectance readings run less accurate on darker skin.
Home-measured blood pressure predicts cardiovascular events at least as well as office readings, and self-monitoring paired with clinician support lowers pressure modestly for a year or…
Where the evidence lands: A validated upper-arm cuff used within a supported care program is one of the best-evidenced home-health tools; an unvalidated device, or a lone cuff without any follow-up, is not.
Grip strength — a few seconds of squeezing a handle — predicts death, disability, and cognitive decline across millions of study participants, in one landmark 17-country cohort better than…
Where the evidence lands: Low grip strength is one of the most robust and reproducible risk markers in aging research; whether raising it lowers mortality is unproven, although resistance training reliably raises the number itself.
Reverse osmosis strips 90–99% of water's natural minerals. Remineralization drops put magnesium and calcium back — a sensible restoration with a genuinely mixed evidence base behind it.
Where the evidence lands: Higher magnesium intake (including from drinking water) is observationally linked to lower blood pressure and cardiovascular risk, and magnesium supplements modestly lower blood pressure in trials — but no study has tested mineral drops themselves, and drops deliver small doses relative to dietary needs.
14 articles · topic hub → · shop this category →
Epigenetic clocks predict mortality consistently across populations and unreliably within one person: technical noise alone produced replicate deviations of up to 9 years in six standard…
The Omega-3 Index promises to turn fish-oil status into a single percentage you can track. The biomarker is scientifically serious — and the leap from a higher index to a longer life…
Where the evidence lands: A higher Omega-3 Index is consistently associated with lower all-cause and cardiovascular mortality across dozens of cohorts (roughly 30% lower fatal CHD risk near 8% versus 4%), but that is association — large supplementation trials were neutral, and one 2024 analysis flagged higher atrial fibrillation and stroke risk with fish-oil use.
Because every atherogenic particle carries exactly one apoB molecule, an apoB test counts plaque-forming particles directly — and in a 233,455-person pooling it beat LDL-cholesterol by…
Where the evidence lands: ApoB refines cardiovascular risk especially in diabetes, obesity, or high triglycerides, where LDL-C misleads; it is a risk marker rather than a treatment, and not yet recommended as routine universal screening.
Cortisol patterns track mortality and cardiovascular risk across large cohorts, and late-night salivary cortisol screens for Cushing syndrome at roughly 92% sensitivity and 96% specificity…
Where the evidence lands: Cortisol is a genuine research biomarker with a narrow validated clinical use; as an individual 'stress damage' diagnostic, a consumer saliva test is weak.
Serum ferritin is the standard window into the body's iron stores — and iron status bends both ways: deficiency drags down energy and resilience, while overload tracks with diabetes and…
Where the evidence lands: Ferritin's clearest value is diagnosing iron deficiency and iron overload; within the normal range it was not associated with mortality in a large national cohort, and because inflammation itself raises ferritin, every reading needs context.
HOMA-IR turns one fasting blood draw into an index of insulin resistance — validated against the clamp, predictive of diabetes and cardiovascular disease in large cohorts, and yet…
Where the evidence lands: Fasting insulin and HOMA-IR are useful, validated surrogate markers of insulin resistance; they are not a diagnosis, they have no universal threshold, and some important associations weaken or vanish with age.
Lp(a) is 80–90% genetically determined, elevated in roughly one in five people, and causally linked to heart attack, stroke, and aortic valve disease — yet it is absent from standard…
Where the evidence lands: Testing Lp(a) once is well supported for risk stratification; because no Lp(a)-lowering drug is yet approved, a high result currently guides aggressive management of everything else rather than a specific treatment.
Largely independent of muscle mass, diet, age, and sex, cystatin C-based eGFR flags more chronic kidney disease than creatinine alone (13.7% vs 9.7% below 60) and predicts death and…
Where the evidence lands: Cystatin C is the confirmatory kidney measure current guidelines recommend combining with creatinine; it sharpens risk prediction but is not flawless — and it is a biomarker, not a product endorsement.
GGT is a cheap, old liver enzyme test that keeps showing up in mortality studies — even within the normal range. The associations are real and consistent; whether the number causes…
Where the evidence lands: Higher serum GGT, even inside the reference range, is consistently associated with higher all-cause and cardiovascular mortality and several chronic diseases — but the evidence is observational, a Mendelian-randomization study found no causal effect on diabetes, and the test is too nonspecific to interpret alone.
High-sensitivity CRP measures the faint background inflammation that tracks with heart attack, stroke, frailty, and dementia — and two landmark trials proved the risk it flags is…
Where the evidence lands: hs-CRP is a validated marker of residual inflammatory cardiovascular risk — useful, non-specific, and best repeated when you are well — but Mendelian randomization indicates CRP itself is probably not the culprit, and for most people it adds only modest predictive value beyond traditional risk factors.
Across cohorts totaling millions, weaker grip strength tracks higher all-cause and cardiovascular mortality as well as or better than systolic blood pressure — a powerful marker of…
Where the evidence lands: Grip strength is a cheap, well-normed vital sign of aging; know your number against age- and sex-specific ranges, but treat it as a prompt for overall strength and activity, not a target in itself.
CGMs reveal biological variation, but a visible glucose spike is not automatically harmful and consumer feedback has not been shown to improve long-term outcomes in healthy people.
Where the evidence lands: A CGM trace is not a direct health score. Healthy people show variable post-meal responses, sensor and plasma values can disagree, and outcome benefits from consumer CGM use remain unproven.
The headline is based on a higher-risk subgroup, not the trial population as a whole. Hearing care still delivered a large and durable communication benefit.
Where the evidence lands: ACHIEVE found no cognitive benefit in its full 977-person trial population. The widely quoted 48% reduction came from a prespecified higher-risk subgroup; hearing-related communication improved substantially and durably across the trial.
The ApoB Home Test Kit measures apolipoprotein B, which may be a more accurate indicator of cardiovascular risk than traditional cholesterol tests.
Where the evidence lands: The ApoB Home Test Kit, by measuring apolipoprotein B particle count, offers a potentially more accurate way to assess cardiovascular risk compared to traditional cholesterol tests, but it should be used as part of a broader health management strategy and in consultation with a healthcare professional.
13 articles · topic hub →
Nearly every NAD+ supplement starts from the same premise: levels fall as we age. In small studies of human skin, brain, muscle and liver, the premise mostly holds. In blood, the largest…
In April 2026 a glaucoma patient in Glendale, California received an injection of ER-100 — three of the four Yamanaka factors, delivered by a viral vector — the first time partial cellular…
Where the evidence lands: Cellular reprogramming has restored vision and extended lifespan in mice and has now reached a first-in-human safety trial in the eye — but no rejuvenation benefit has been shown in any person, and the five-year ER-100 trial exists precisely to find out whether the approach is safe enough to test for benefit.
A 2009–2012 CDC survey analysis found periodontitis in 46% of dentate American adults 30 and older. Pooled cohorts of 5.71 million people link it to earlier death, and the count of…
Where the evidence lands: A CDC analysis of 2009–2012 survey data found periodontitis in 46% of dentate US adults 30 and older (8.9% severe). In pooled cohorts of 5.71 million people, periodontitis is associated with all-cause mortality RR 1.46 and edentulism with 1.66; a USPSTF meta-analysis of incident coronary disease in initially CHD-free adults puts the adjusted association at a more modest 1.24 to 1.34. Trials: periodontal treatment transiently worsened, then improved endothelial function (flow-mediated dilation +2.0% at 180 days); CRP averaged 0.50 mg/L lower after therapy, on evidence the reviewers graded modest; the two major glycemia trials split (DPTT, n=514, 6 months, nonsurgical: no HbA1c effect, stopped for futility; a 12-month intensive-treatment trial, n=264: HbA1c 0.6% lower). Tooth count at 70 predicted 7-year mortality (HR 0.96 per tooth) and tooth loss predicted disability and 21-year mortality. All mortality, disability and dementia evidence is observational; the trials in this record tested biomarkers and glycemia, not hard outcomes.
The poster prices loneliness at fifteen cigarettes a day. The abstracts say something more careful and more useful: disconnection carries mortality-grade risk that is “comparable with…
Where the evidence lands: The abstract-supported version of the viral claim: social disconnection's influence on mortality is “comparable with well-established risk factors” (148-study meta, 308,849 people, OR 1.50 for survival with stronger relationships; strongest for complex integration at 1.91, weakest for the living-alone binary at 1.19, not statistically significant) and isolation “predicted mortality… as did smoking and high blood pressure” in NHANES III — but no abstract prices it in cigarettes. The feeling and the fact dissociate: pooled estimates run +29% mortality for isolation, +26% for loneliness, +32% for living alone (and larger in samples averaging under 65), yet in adjusted cohort models the HRS found loneliness itself predicting death (HR 1.45, living situation and depression controlled), while ELSA (isolation 1.26 vs loneliness 0.92) and UK Biobank (1.26 vs 0.99 fully adjusted, with mediators plausibly on the causal pathway) found the fact outlasting the feeling. Cardiovascular slice: +29% coronary disease, +32% stroke. All of it observational — this literature contains no randomized trial testing connection against mortality; among randomized loneliness interventions, those addressing maladaptive social cognition (the lens, not the calendar) worked best.
A Science study followed molecular changes in 335 women. Individual trajectories complicate the idea that one average curve describes how everyone ages.
Where the evidence lands: Repeated measurements can reveal individual variation. They do not by themselves establish a treatment that slows aging.
A Nature Medicine study examines organ-age models separately by sex. Better references may sharpen research, but a clock score is not a rejuvenation prescription.
Where the evidence lands: Sex-specific references can reveal differences in research models. They do not establish an individual aging rate or a treatment that reverses aging.
The national count is a demographic milestone. It does not measure disease-free years or prove a longevity diet.
Where the evidence lands: Population counts describe exceptional survival; they do not establish individual treatment or supplement benefits.
Tea, berries and spices were associated with a changing DNA-methylation clock in a small lifestyle trial. That is a research clue, not an age-reversal menu.
Where the evidence lands: Preliminary human biomarker evidence. Exploratory food associations do not establish individual food effects, whole-body rejuvenation or longer life.
A new cell study explains how pterostilbene may change lipid metabolism. Human trials show why the finding needs careful limits before becoming a supplement or fat-loss claim.
Where the evidence lands: Pterostilbene reduced lipid accumulation in cultured mouse muscle cells. That result does not establish fat loss or improved muscle health from blueberries or supplements in people; human trials add mixed metabolic and null muscle-recovery findings.
A new study connects a membrane protein to AKT signaling, senescence and mouse lung fibrosis. Earlier human-cell experiments show why the direction of intervention still needs careful…
Where the evidence lands: PTCHD4 is a preclinical research lead whose effects differ across experimental contexts. The reported mouse and cell findings do not establish a safe human anti-aging intervention.
An exercise-linked signal produced intriguing results in Alzheimer’s mouse models. Here is what the experiments establish—and what they cannot tell us about treating people.
Where the evidence lands: Irisin is a research lead supported by mechanistic experiments, not a proven dementia treatment or a basis for naming a best leg workout.
The most widely cited number in the caregiving literature, a 63 percent rise in mortality, belonged to strained elderly spouses rather than to caregivers as a group; a propensity-matched…
Where the evidence lands: The famous 63 percent mortality increase (Schulz & Beach, 1999) applied only to elderly spousal caregivers reporting strain — unstrained caregivers showed no elevation (RR 1.08) — and a propensity-matched national analysis of 3,503 caregivers later found an 18 percent LOWER death rate than matched noncaregivers, with no at-risk subgroup even by strain. The reliable toll is psychological (meta-analytic effect sizes ~0.55–0.58 for stress and depression) with a small average physical-health difference (0.18); mechanism studies link chronic psychological stress to slower wound healing in caregivers (48.7 vs 39.3 days for an identical biopsy wound) and to shorter telomeres in high-stress women. Randomized trials back structured support: REACH II's 12-session program cut clinical depression prevalence from 22.7% to 12.6%, and NYU's counseling-plus-support-group program reduced the nursing-home placement rate 28.3%, delaying the model-predicted median time to placement by 557 days, with 61.2 percent of the effect running through the caregiver's own support, coping and mood. Respite care, the most-advocated support, remains an evidence gap (Cochrane: 4 trials, 753 participants, very low quality, no demonstrated effect).
Rentosertib has renewed the debate over biological age. A randomized human experiment offers an important lesson: changing one aging measure does not establish that people live longer.
Where the evidence lands: A clock can predict mortality without being a validated substitute for survival in a treatment trial. CALERIE changed DunedinPACE but did not significantly change PhenoAge or GrimAge.
11 articles · topic hub → · shop this category →
Topical niacinamide at 4–5% over 8–12 weeks modestly improves fine lines, hyperpigmented spots, blotchiness, and barrier function in mostly split-face trials — real, gradual,…
Hyaluronic acid holds a thousand times its weight in water, declines with age, and has genuine randomized-trial support for skin hydration — topical and now oral. But wrinkle effects are…
Where the evidence lands: Topical hyaluronic acid reliably improves skin hydration and elasticity in controlled studies, with low-molecular-weight forms reducing wrinkle depth, and oral HA shows benefit over 8–12 weeks — but effects on wrinkles are modest, most trials are small and industry-linked, and the gains are largely hydration, not structural renewal.
Topical vitamin C has real, controlled-trial support for photoaged skin — fine lines, texture, pigmentation — but the trials are small, the formulations vary, the molecule is notoriously…
Where the evidence lands: Consistent use of a well-formulated vitamin C serum can measurably improve the appearance of photodamaged skin over weeks to months, but evidence is limited for L-ascorbic acid specifically, results depend on formulation stability, and this is dermatology, not longevity medicine.
Bakuchiol is marketed as retinol's gentler plant twin. A 12-week randomized trial backs the comparison — less scaling and stinging, comparable wrinkle results — but reviewers grade the…
Where the evidence lands: A 12-week randomized, double-blind trial found topical bakuchiol comparable to retinol for wrinkles and hyperpigmentation with less irritation, but the total evidence base is small, often unblinded, and high risk of bias — its best-established advantage is tolerability.
Copper tripeptide-1 stimulates collagen in the lab and connective tissue in rat wounds, and it has become a skincare-forum obsession. But the best controlled human test — a randomized…
Where the evidence lands: GHK-Cu has a strong mechanistic and animal case as a skin-remodeling signal, but rigorous human cosmetic evidence does not exist: no adequate placebo-controlled trials for photoaging or wrinkles, and the best controlled trial found no objective benefit over control — so treat it as a plausible supportive ingredient, not a proven anti-aging treatment.
Topical tranexamic acid significantly reduces melasma severity in randomized trials and meta-analyses, performing comparably to hydroquinone with fewer irritant effects — though trials are…
Where the evidence lands: For melasma and facial hyperpigmentation, topical tranexamic acid is one of the better-evidenced cosmeceuticals — effective at 2–5% concentrations over 8–12 weeks — but it manages a relapsing condition rather than curing it, and anti-aging claims are extrapolation.
Retinaldehyde is one enzymatic step from retinoic acid, the most proven molecule in topical anti-aging — and small randomized trials show it improves fine lines, texture, and hydration…
Where the evidence lands: Topical retinaldehyde at 0.05–0.1% has real randomized-trial support for improving photoaged skin's appearance with better tolerability than prescription retinoic acid — but the evidence base is small, short, and largely about how skin looks, not about aging itself.
Topical azelaic acid is one of the few skincare actives with high-certainty randomized-trial evidence — for papulopustular rosacea, at prescription strengths of 15–20%. What a roughly 10%…
Where the evidence lands: For inflammatory rosacea lesions and redness, azelaic acid has among the strongest evidence of any topical; expect one to two months before benefit, transient stinging as the common side effect, no effect on visible vessels, and weaker certainty at over-the-counter doses.
Alpha-lipoic acid is a potent, unusually versatile antioxidant, and one good split-face trial found a 5% cream measurably reduced facial roughness over 12 weeks. But controlled long-term…
Where the evidence lands: A randomized split-face trial showed 5% topical alpha-lipoic acid reduced skin roughness more than vehicle after 12 weeks (50.8% vs 40.7% on laser profilometry), supported by a smaller gel study — plausible, modest improvement in texture and fine lines, not systemic anti-aging, with long-term evidence still thin.
Human biopsy and controlled-trial evidence shows topical glycolic acid thickens epidermis, raises collagen and hyaluronic acid, and modestly improves photodamage and sallowness — while…
Where the evidence lands: Glycolic acid has real tissue-level evidence for texture, tone, and some photoaging markers; wrinkle benefits are modest and cumulative, and peel-strength products demand professional supervision.
In a randomized Australian trial, adults assigned to daily sunscreen showed no detectable increase in skin aging over 4.5 years and about 24% less photoaging than discretionary users;…
Where the evidence lands: Regular broad-spectrum sunscreen is one of the few anti-aging interventions with randomized-trial support — for photoaging and melanoma — though high-quality trials are few, certainty for keratinocyte cancers is lower than advertised, and sunscreen is no license for longer sun exposure.
6 articles · topic hub →
A semaglutide trial moved epigenetic clocks, but weight loss, organ protection, biomarkers and lifespan are four different claims.
Protein can activate growth signaling and preserve muscle. Human evidence says the right question changes with age, food source, training, and kidney health.
Where the evidence lands: Protein is neither a universal longevity accelerator nor a toxin. Human data support adequate protein and resistance training for muscle preservation, especially later in life, while mortality cohorts more consistently favor plant sources than any single total-protein target.
Reactive oxygen species can damage cells, but they also carry essential signals. Large trials show why an antioxidant pill is not bottled longevity.
Where the evidence lands: Antioxidant-rich foods and high-dose antioxidant pills are not interchangeable. Randomized trials do not show a general longevity benefit from antioxidant supplements, and beta-carotene, vitamin A, and vitamin E have caused harm in specific doses and populations.
A small Alzheimer feasibility trial found administration was possible but did not establish cognitive rejuvenation, disease modification, or benefit in healthy adults.
Where the evidence lands: Young-plasma enthusiasm comes from complex animal experiments. The small human Alzheimer trial established feasibility, not cognitive benefit or age reversal in healthy people.
Both target core aging pathways and both are studied for healthspan, but they are prescription-only, not sold here, and the human data carry real caveats.
Where the evidence lands: Rapamycin and metformin hit real aging pathways and show early human signals, but both are prescription-only with meaningful risks, including metformin blunting exercise gains, and neither is a proven longevity treatment.
Harvard's ClockBase platform analyzes thousands of datasets across 40+ aging clocks to uncover aging interventions and disease links, but stresses that no single biological age number is…
Where the evidence lands: ClockBase reveals that while aging clocks like Horvath and DunedinPACE can uncover promising longevity interventions and disease links, the clocks often disagree, so trends matter more than any single biological age number.
6 articles · topic hub → · shop this category →
A look at whether topical capsaicin cream like Capzasin-HP actually relieves pain, based on scientific studies.
Evidence suggests the Salonpas Pain Relieving Patch can provide temporary relief for minor musculoskeletal pain.
Where the evidence lands: The Salonpas Pain Relieving Patch can provide temporary relief for minor musculoskeletal pain based on clinical studies, but does not address underlying causes or directly impact longevity.
A look at the evidence for topical lidocaine's effectiveness in managing pain.
Where the evidence lands: Aspercreme 4% lidocaine cream may provide some localized pain relief, especially for neuropathic pain, but the evidence is mixed and expectations should be realistic based on the lower concentration and limited data on topical analgesics.
A look at the evidence for Biofreeze Menthol Pain Relief Gel’s effects on pain and its implications for longevity and healthspan.
Where the evidence lands: Biofreeze Menthol Pain Relief Gel may provide temporary, symptomatic relief for certain types of pain, but there is no evidence it directly impacts longevity or healthspan.
Creams, gels and patches all promise fast relief — here is which mechanisms hold up in human trials, ranked by the evidence.
Where the evidence lands: Among over-the-counter pain topicals, only diclofenac has strong human evidence; capsaicin and lidocaine are reasonable for the right kind of pain, and menthol-based products mainly deliver fast comfort.
How this topical NSAID delivers targeted pain relief for arthritis – without the dangers of oral anti-inflammatories.
Where the evidence lands: Voltaren Arthritis Pain Gel provides effective, localized pain relief for osteoarthritis – particularly in the knees – with significantly fewer risks than oral NSAIDs, helping you stay active and comfortable as you age.
5 articles · topic hub → · shop this category →
A look at what consumer wearables like the Garmin Forerunner 265 can and can’t tell us about healthspan.
In diabetes, continuous glucose monitoring cuts time in hypoglycemia by 38% to roughly half and trims HbA1c modestly; in people without diabetes, the evidence shrinks to modest short-term…
Where the evidence lands: CGM is among the best-evidenced tools in diabetes care — especially for hypoglycemia avoidance — but for healthy biohackers it generates data without proven prevention or longevity benefit.
With roughly 15% of 'gluten-free' foods contaminated in meta-analysis and accidental exposures running near 14% per year in peanut-allergic children, handheld sensors offer a real but…
Where the evidence lands: A validated portable gluten sensor can be a reasonable spot check for high-risk meals — as a supplement to label reading, staff communication, and epinephrine preparedness, never a replacement.
A body-composition scale tracks biomarkers genuinely linked to cardiovascular risk and mortality, but consumer bioimpedance readings are trend-level approximations, the behavioral evidence…
Where the evidence lands: Read the numbers as trends inside a structured program: the underlying biomarkers matter, the single morning reading does not, and stand-alone weighing advice without support has failed in trials.
Consumer wearables now measure sleep, heart rate and HRV well enough to survive comparison with laboratory gold standards — and the signals they track genuinely predict mortality in large…
Where the evidence lands: Modern wearables measure sleep-versus-wake, heart rate and HRV with clinically respectable accuracy, and those biomarkers robustly predict long-term health — but the evidence is about the signals, not about any device extending life.
Browsing the store instead? Open the article feed in the Magellan app →